Neurocrine Biosciences
NBIX
NBIX
121 hedge funds and large institutions have $1.12B invested in Neurocrine Biosciences in 2014 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 54 increasing their positions, 23 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
19% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 26
3% more funds holding
Funds holding: 117 → 121 (+4)
Holders
121
Holding in Top 10
2
Calls
$10.4M
Puts
$7.04M
Top Buyers
| 1 | +$45.4M | |
| 2 | +$19.3M | |
| 3 | +$18.8M | |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$16.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$15.2M |
Top Sellers
| 1 | -$13M | |
| 2 | -$8.12M | |
| 3 | -$7.76M | |
| 4 |
VM
VHCP Management
New York
|
-$6.3M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.15M |